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Introduction
The finding that clinical outcome is linked to the immunoglobulin mutational status in chronic lymphocytic leukaemia (CLL) focused attention on the role of the B cell receptor (BCR) in this disease. [1] [2] [3] The clinical success of the BTK inhibitor ibrutinib and the PI3K inhibitor idelalisib has further highlighted a key role of the BCR. Interestingly, treatment-naive M-CLL cases tend to respond more slowly to ibrutinib and to have fewer complete remissions than U-CLL. 4 This difference could reflect the fact that, although sIgM expression and signal capacity is down-modulated in all cases compared to normal B cells, U-CLL samples tend to retain higher levels of surface IgM (sIgM) expression and signalling capacity compared to M-CLL [5] [6] [7] [8] . Although the drivers of BCR signalling in CLL are unknown, in vitro investigations suggest microbial-derived antigens, autoantigens and autonomous signals could be involved. [9] [10] [11] [12] Antigen/autoantigen binding to the BCR results in phosphorylation of CD79A and CD79B by Src family kinases 13 , leading to assembly and activation of the signalosome which comprises proteins essential for BCR-induced signal transduction including BTK and PI3K 3 . sIgM expression appears to be the main determinant of variable sIgM-signalling capacity 5 . However, the specific factors that may influence sIgM expression in CLL cells are not known.
Binding of IL-4 to the IL-4 receptor (IL-4R) on B cells results in JAK1/3-mediated phosphorylation of STAT6 (pSTAT6). 14 pSTAT6 dimerizes and translocates to the nucleus where it induces expression of multiple target proteins (including Bcl-2 family members, Bcl-XL and Mcl-1, 15 MHCII and CD23) and promotes immunoglobulin class switching. 16, 17 Moreover, IL-4 is also important for B-cell proliferation and differentiation, and the formation of the germinal centers in mice. [18] [19] [20] In CLL samples, IL-4 suppresses basal and chemotherapy-induced apoptosis 15, [21] [22] [23] , probably via increased expression of anti-apoptotic proteins 15 .
IL-4 is one of the cytokines classically synthesised by CLL T cells 24, 25 . Importantly, CLL patients with progressive disease have been reported to have a significantly greater number of T cells that spontaneously produced IL-4 compared to patients with non-progressive disease or healthy individuals. 26 CLL cells themselves express a significantly greater number of IL-4 receptors (IL-4R) compared to normal B cells, 27, 28 and this is consistent with increased pSTAT6 expression in CLL samples, 29 consequent to the augmentation of STAT6-dependent signalling pathways. Furthermore, in an adoptive transfer model of CLL, T cells were essential for tumour engraftment. 30 Together these data suggest a role for T cells and perhaps IL-4 in CLL biology.
IL-4 has previously been shown to induce sIgM expression and signalling capacity in murine splenic B cells 31, 32 . An early study on the effects of IL-4 on αIgM-induced proliferation using six CLL samples showed a heterogeneous response which could have reflected changes in levels of sIgM, but this was prior to the description of the two subsets of disease 33 . Here, we show that IL-4 also augments sIgM expression and signalling in the majority of CLL samples. Importantly, we show that IL-4 partially overcomes ibrutinib-or idelalisib-mediated inhibition of sIgM signalling. Stimulatory effects of IL-4 were reversed using JAK3 or STAT6 inhibitors. These results suggest that the ability of IL-4 to enhance effects of antigen in tissues may have been captured by CLL cells to promote tumorigenesis.
Methods

Patient and normal donor samples
Diagnosis of CLL was according to the IWCLL-NCI 2008 criteria. 34 Seventy-four CLL cases were studied following informed written consent in accordance with ethics committee approvals under the declaration of Helsinki ( Supplementary Table 1 ). Procedures for the isolation of malignant cells and the determination of their purity have been described previously. 5 All isolates contained >90% CD19 + CD5 + cells. Normal donor peripheral blood mononuclear cells (PBMC) were obtained from anonymized leukocyte cones from the National Blood Service (Southampton, UK) following ethical approval. PBMCs were obtained using density gradient centrifugation (Lymphoprep), resuspended in cryopreservation medium (90% fetal calf serum, 10% DMSO) and frozen in liquid nitrogen prior to use in order to replicate our procedure with CLL PBMCs.
Cell culture and protein extraction
CLL cells were cultured and protein extracted as previously described. 15, 35 Soluble anti-IgM F(ab')2 was used at 20µg/ml 5 , bead bound immobilised anti-IgM F(ab')2 was added at 2:1 ratio, bead:CLL cell as previously described. 36 
Flow Cytometry
Cells were labelled for 30 minutes at 4°C with antibodies conjugated to various fluorochromes. Data were acquired on a BD FACSCanto II. All mean fluorescence intensity (MFI) and percent positive staining were measured relative to an isotype control. Detection of intracellular calcium was quantitated following incubation with 4µM Fluo3-AM (Life Technologies, UK) and 0.02% (vol/vol) Ionomycin (Sigma) was added as a positive control. Analysis was performed using Flowjo v10.
Biotinylation of cell-surface proteins
Biotinylation, isolation of cell surface proteins and digestion using endoglycosidase H (EndoH) was performed as previously described. 37 
Gel electrophoresis and Immunoblotting
Proteins were separated on 12% polyacrylamide gels (Thermo Fisher, UK), transferred to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK) and probed with anti-HSC70 (Santa Cruz, CA), antiactin (Sigma Aldrich, Poole, UK) and anti-Bcl-2 (Dako, Glostrup, Denmark) as loading controls. Anti-CD79B was from Abcam. All other antibodies were from Cell Signaling Technology (Hitchin, UK). Bands were detected by incubation with HRP-linked secondary antibodies (Dako), enhanced chemiluminescence reagents (Thermo Scientific, Rockford, IL) and visualised using the ChemiDoc-It imaging system (UVP, UK). Band intensities were quantified using ImageJ and normalised to HSC70, Actin or Bcl-2 as indicated.
Results
IL-4 enhances sIgM expression in B cells from healthy human donors
Previous studies have demonstrated that IL-4 enhances sIgM expression in murine B cells. 31, 32 Before initiating studies in CLL samples, we investigated the effects of IL-4 in normal human B cells. PBMCs were obtained from 5 individual donors and sIgM expression analysed on the naive (CD19 + CD27 -) and memory (IgG -CD19 + CD27 + ) B-cell populations using flow cytometry ( Figure 1A ). PBMCs were treated for 24h with IL-4 or the vehicle control (RPMI1640 supplemented with 10% fetal calf serum and antibiotics) prior to evaluation of sIgM levels. IgM-memory B-cells expressed higher levels of sIgM compared to naive B-cells as previously demonstrated 38 ( Figure 1B ). The IL-4-induced fold-increase in naive cells (mean 2.7-fold) was significantly greater than that of IgM-memory cells (mean 1.5-fold; p=0.0012). Modulation of sIgM was not secondary to effects of IL-4 on cell death since the proportion of dead cells was low (<5%) and not effected by IL-4 in either B-cell subset (data not shown).
IL-4 target gene expression in CLL cells in vivo
We performed gene-set enrichment analysis (GSEA) 39 to investigate potential effects of IL-4 in CLL patients in vivo. We identified a set of IL-4-regulated genes from a previously published study of CLL cells following treatment in vitro with IL-4 40 , and investigated whether these specific target genes were enriched in the transcriptional profiles of CLL cells purified from lymph node (LN) compared to matched blood and bone marrow. 41 GSEA revealed a significant enrichment of expression of IL-4-target genes in LN-derived CLL cells, compared to CLL cells isolated from the other tissues ( Supplementary Figure 1) , consistent with IL-4-dependent transcriptional activity in CLL LN in vivo.
IL-4 enhances expression of sIgM on CLL cells.
We investigated the effects of IL-4 on expression of sIgM on CLL cells isolated from the blood of patients. In our initial analysis, CLL samples were treated with or without IL-4 (10 ng/ml), and sIgM expression quantified by flow cytometry at the start of the experiment, and at various times up to 72 hours. A representative sample is shown ( Figure 2A ) and summarised data are presented ( Figure 2B ).
As previously demonstrated, 5 incubation in vitro without IL-4 was associated with a modest increase in sIgM expression, which was most evident at 72 hours. Compared to the vehicle control, IL-4 increased sIgM expression at all time points. Due to potential confounding effects of apoptosis at later time points (48-72h), we extended the analysis by investigating effects of IL-4 on sIgM expression at 24 hours in additional samples. In this extended analysis (n=33 samples), IL-4 increased overall sIgM expression ( Figure 2C ). However, there was variability in response between individual samples. In contrast to sIgM, IL-4 treatment on the whole did not significantly alter expression of sIgD, although a small subset with sIgD MFI levels >40 (in grey) increased their receptor expression in response to IL-4 ( Figure 2D -F). We investigated whether the variation in effects of IL-4 on sIgM expression at 24 hours correlated with CLL prognostic markers. IL-4-increased sIgM expression was significantly greater in U-CLL compared to M-CLL (p=.0016) ( Figure 2G ) and in ZAP70+ compare to ZAP70-samples (p=.016) ( Figure 2H ). In contrast, IL-4 effects were not significantly different between CD38+ and CD38-samples ( Figure 2I ).
Effects of IL-4 on sIgM expression are mediated via JAK/STAT signalling
We investigated effects of IL-4 on JAK3-mediated pSTAT6. CLL cells were treated with varying concentrations of IL-4 (0.1-10 ng/ml) for 24 hours, and pSTAT6 quantified by immunoblotting. IL-4 induced a dose-dependent increase in pSTAT6 with a maximal response detected at concentrations >1ng/ml ( Figure 3A ) and was paralleled by increased sIgM expression ( Figure 3B ), but not sIgD ( Supplementary Figure 2A ). We also investigated responses to additional cytokines, including IL-13 (a known inducer of pSTAT6) 16 , IL-2, IL-6, IL-8, IL-10, and IL-21. Only IL-4 increased pSTAT6 and sIgM expression ( Figure 3C -D). The type II IL-4R which regulates IL-13 signalling, is generally the exclusive receptor expressed by non-hematopoietic cells, and may partially explain the lack of pSTAT6 induced by IL-13. 42, 43 None of the cytokines altered expression of sIgD (Supplementary Figure 2B ).
To directly investigate the role of JAK3/STAT6 signalling in IL-4-mediated sIgM induction, CLL cells were pre-treated for 1 hour with the JAK3 inhibitor tofacitinib (CP; 10M) or the STAT6 inhibitor AS1517499 (AXON; 1M) and then incubated for an additional 23 hours in the presence or absence of IL-4 before analysis of sIgM expression. Inhibitor concentrations selected for these experiments were based on initial titration experiments to identify optimal inhibitory concentrations (Supplementary Figure 2C -D). AS1517499 and Tofacitinib had no effect on sIgM expression when tested alone, but completely blocked the ability of IL-4 to enhance sIgM expression ( Figure 3E ). The inhibitors had no effects on CLL cell viability at times up to 24 hours (data not shown). Therefore, IL-4-induced increases in sIgM expression appear to be mediated via JAK/STAT signalling.
Increased sIgM expression is associated with higher sIgM signalling capacity in IL-4-treated cells
We investigated whether the ability of IL-4 to increase sIgM expression at 24 hours was associated with increased receptor function using intracellular calcium fluxes as a highly quantitative measure of signal responses 5 . IL-4 increased anti-IgM-induced calcium mobilisation, shown in a representative sample ( Figure 4A ) and summarised in a larger cohort ( Figure 4B Figure 4A ).
IL-4 increases CD79B expression
We investigated the effects of IL-4 on expression of CD79A and CD79B, two consort molecules which are essential for sIgM expression and signalling 44 . β2 microglobulin and Bcl-2 were used to normalise loading for RNA and protein analysis respectively, since their expression did not change upon IL-4 treatment. IL-4 increased expression of CD79B at the RNA ( Figure 5A ) and total and surface protein ( Figure 5B -C, Supplementary Figure 3A ) at 24h. In contrast, IL-4 treatment resulted in a slight reduction in expression of CD79A RNA ( Figure 5A ) but with no discernible effects on protein expression ( Figure   5B ). Similar to effects on sIgM expression, effects of IL-4 on CD79B were greater in U-CLL compared to M-CLL samples ( Figure 5D ). However, no difference in IL-4R expression was observed between U-CLL and M-CLL in a small cohort of CLL (Supplementary Figure 3B) , indicating IL-4R expression does not explain the differential response between the CLL subsets.
IL-4 increased expression of the "mature" sIgM glycoform
Previous investigations by our group found that the µ-chain of sIgM in CLL cells exists in two forms with distinct N-glycosylation patterns; a mature (fully glycosylated) glycoform typical of normal B cells and an immature (high mannose) glycoform more characteristic of IgM in the ER, but found on the cell surface after BCR-mediated activation. 37 Incubation of CLL cells in vitro led to a restoration in expression of the mature sIgM glycoform 37 . To investigate effects of IL-4, we analysed the expression and glycosylation of µ-chain using whole cell lysates and cell surface protein-enriched fractions, isolated by biotinylation and streptavidin capture. A representative sample is shown ( Figure 5E ) and summarised for 12 samples ( Figure 5F ). Although whole cell expression of µ-chain was not altered, IL-4 significantly increased the relative abundance of the mature µ-chain glycoform on the cell surface (SP) as shown by increased expression of a more slowly migrating protein band ( Figure 5E ). In one case with pre-existing high levels of the mature glycoform, this was stable ( Figure 5F ). Incubation with endoglycosidase H to remove terminal mannose selectively removed glycans from the more rapidly migrating protein, confirmed that this glycoform contained high mannose ( Figure 5E ). Therefore, IL-4 appears to enhance the ability of CLL cells to replace the immature sIgM glycoform with the fully glycosylated form typical of resting normal B cells, but without changes in overall µ-chain expression.
Effect of IL-4 on apoptosis and on inhibition of sIgM signalling by ibrutinib and idelalisib
IL-4 appears to protect against ibrutinib and idelalisib induced apoptosis 45, 46 . Here we investigated whether IL-4 influenced the response of CLL cells to drug-induced inhibition of the BCR signalling pathway at concentrations in accordance with the literature 45, 46 . CLL samples were treated with IL-4 for 23h and then pre-treated with kinase inhibitors for 1h prior to anti-IgM induced calcium flux. A representative experiment is shown ( Figure 6A-B) , and the data summarised ( Figure 6C Figure 4D ). IL-4 treatment had no impact on the expression of BTK or PI3Kδ at the mRNA or protein level indicating that the reduced sensitivity to idelalisib and ibrutinib was not due to reduction in expression of their target protein (data not shown). Therefore, IL-4 may reduce the inhibitory effects of BCR kinase inhibitors.
The effect of IL-4 on other cell surface receptors
We investigated whether IL-4 modulated expression of other receptors important for CLL cell behaviour. We initially focused on CXCR4 which is thought to play an important role in homing and retention of CLL cells in LNs 47, 48 . CXCR4 is down-modulated on tissue-localised CLL cells 41 (presumably due to ligand-induced receptor endocytosis) and we have shown that culture of CLL cells in vitro is associated with a recovery of CXCR4 expression 49 . We therefore investigated whether IL-4 modulated this natural recovery by incubating cells in the presence or absence of IL-4 and quantifying CXCR4 expression by flow cytometry. A representative sample is shown ( Figure 7A ) and the data summarised Figure 5A -C). As previously shown 49 , culture in vitro was associated with a substantial increase in CXCR4 which peaked at 24 hours. However, in contrast to effects on sIgM, IL-4 significantly reduced CXCR4 expression. Overall, IL-4 reduced CXCR4 expression by ~50% at 24 hours ( Figure 7C ) and by 72 hours CXCR4 expression was almost undetectable ( Figure   7B ). Effects on CXCR4 were specific for IL-4 amongst tested cytokines ( Figure 7D ) and effectively blocked by JAK3 or STAT6 inhibition ( Figure 7E ). Consistent with reduced CXCR4 expression, IL-4 also reduced CXCL12-dependent CLL cell migration ( Figure 7F ). In a subset of CLL samples treated with IL- Figure 5C ). This indicated that the effects of IL-4 may be cell specific. The reduction in CXCR4 protein levels in CLL cells was also transcriptionally regulated, since IL-4 also reduced CXCR4 mRNA levels (Supplementary Figure 5D ). IL-4 also reduced expression of the related chemokine receptor CXCR5 (Supplementary Figure 5E-F) .
(Figures 7B and C and Supplementary
4, we also investigated CXCR4 expression in CD19 -CD5 + cells (T cells). In contrast to the CLL cells, IL-4 treatment of CD19 -CD5 + cells resulted in an increase in CXCR4 expression (Supplementary
The modulatory effects of IL-4 were investigated on additional cell surface markers including CD19 and the activation markers CD69, CD23 and CD71 which are generally over-expressed on CLL cells compared to normal donor B cells. 50 Although CD19 and CD71 expression were unaltered, IL-4 increased expression of CD69 and CD23 ( Supplementary Figure 6A-D) . These data indicate a considerable degree of selectivity amongst the receptor modulating effects of IL-4.
Discussion
CLL appears to be a BCR-driven malignancy and the expression of sIgM and subsequent downstream signalling are involved in disease behaviour. Cases of U-CLL, a subset of poorer prognosis, generally express higher levels of sIgM and subsequently produce a stronger signal compared to M-CLL in response to anti-IgM. 3, 51 Clearly there is a potential for microenvironmental factors to influence BCR signaling and previous studies have shown that BAFF and CD40L promote sIgM-mediated signalling in CLL cells 52 . In those studies, regulation appeared to involve an indirect potentiation of intracellular signal transduction via miRNA-155-mediated suppression of the inhibitory phosphatase SHIP1 52 . By contrast, IL-4 appears to promote sIgM signalling, at least in part, via direct upregulation of IgM expression at the cell surface.
GSEA revealed a clear signature of IL-4-mediated transcription in the LN of CLL patients, compared to matched blood and bone marrow samples, indicating that IL-4 may be acting on the malignant cells in the LN tissue. The source of IL-4 remains unknown, but CD4+ T cells are detectable, and are likely to be involved 24, 53 . TFH cells a known source of IL-4 are also increased in the blood of CLL patients and, although unambiguous identification in tissues remains difficult, T cells with features of TFH have been observed in CLL lymph nodes 54 . Interestingly, although circulating T cells from CLL patients have increased exhaustion markers and have impaired proliferation, cytotoxicity and synapse formation 55, 56 they retain their capacity for cytokine production. 56 In terms of effects of IL-4 on CLL cells, we found that sIgM, but not sIgD expression, increased following IL-4 treatment in vitro. Since there was no detectable increase in total cellular IgM following IL-4 treatment, the increase in surface expression may be due to "shunting" of IgM from the endoplasmic reticulum (ER) to the cell surface. The relative increase in the fully N-glycosylated glycoform is consistent with this. Our data in CLL cells are similar to those described in mouse splenocytes where IL-4 promoted sIgM expression, leading to enhanced downstream signalling 31, 32, 57 . In normal mouse splenocytes, there was co-amplification of CD79A and CD79B, consort molecules for sIgM expression 31 , whereas in CLL, there was a clear accompanying increase in CD79B expression, which is consistent with the reports that CD79B limits BCR assembly in CLL 58 . However CD79A protein expression was more difficult to interpret due to the detection of multiple bands on the immunoblot caused by IL-4 induced glycosylation of this protein. It seems therefore that there may not be a defect in the ability of µ chains to undergo N-glycosylation and assembly with CD79A and CD79B in the ER of CLL cells 58 . Instead there appears to be regulation of the subsequent process of movement through the Golgi complex to the membrane, possibly via IL-4-mediated CD79B upregulation. In contrast, there was little effect of IL-4 on sIgD expression, consistent with the suggested reduced dependence on CD79A and CD79B 59 .
Expression in CLL cells of several other receptors (CD19, CD71) did not significantly change following IL-4 pre-treatment, however two key receptors; CXCR4 and CXCR5 which are involved in cell migration into the lymph node were downregulated. In contrast, CXCR4 was upregulated in CD19 -CD5 + cells (Tcells). These results suggested a possible role by IL-4 in recruiting T cells to and retaining B cells within the lymph node. This is also consistent with previous reports where CXCR4 is upregulated by IL-4 in normal peripheral and cord blood T cells. 60 Importantly these data indicated that in CLL the mechanism of IL-4 is both receptor-and cell type-dependent. The IL-4-mediated downregulation of CXCR4 expression and function by CLL cells mirrors the effect of BCR stimulation on this receptor 61, 62 suggesting that these influences may be acting together to locate cells to extrafollicular sites 63 where enhanced IgM expression then increases antigen engagement and subsequent downstream signalling events.
The effects of IL-4 appear to be common to all B cells, since both naive and memory B cells respond to IL-4 in a similar way to CLL cells, however naive CD27 -B-cells responded to a greater extent than CD27 + memory B-cells, indicating that the effect of IL-4 may be dependent on the cell of origin.
Therefore the higher level of response to IL-4 in U-CLL cases may simply reflect its origin from a naïve B cell 49 . We propose that CLL cells may highjack the naturally occurring IL-4 signalling pathway to augment BCR signalling and promote B-cell proliferation and survival, especially within the U-CLL subset.
In addition to effects of IL-4 on sIgM expression and function, we have also shown that this cytokine decreases the inhibitory effects of idelalisib or ibrutinib on anti-IgM-induced signalling and protects against BCR-kinase inhibitor induced apoptosis. The presence of significant numbers of CD4+ T cells in proliferation centers 53 , accompanied by an IL-4 gene signature (above), might lead to an increase in expression of sIgM in non-mobilized tumor cells and therefore could protect a subpopulation from kinase inhibition. The greater effect on U-CLL suggests that CLL cells with more responsive" signaling via sIgM engagement 6-8 may be more sensitive to IL-4. However, the clinical observation of a reduced effect of inhibitors on disease load in M-CLL might be due to the greater proportion of anergic cells, which respond poorly to BCR signals and to IL-4, and would therefore persist during therapy 51 . Since IL-4 effects are mediated by the JAK3/STAT6 pathway, we are currently investigating whether JAK3 inhibition in combination with BCR kinase inhibitors is capable of promoting more durable remissions in vivo in the Eµ-TCL1 mouse model. These data clearly indicate that cytokines operating within the tumour microenvironment enhance BCR signalling, reduce sensitivity to BCRkinase inhibitors and may have relevance for other B-cell malignancies. 
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